HAPPE Spine has been recognized by Orthoworld as one of the orthopedic startups to watch in 2026.
The feature, written by Orthoworld’s Mike Evers, highlights companies pushing the boundaries of what’s possible in orthopedic innovation.
Biomaterial Platform for Bone-Integrating Implants
HAPPE Spine has developed a fully synthetic biomaterial platform for bone integrating implants that look and act more like a biologic. The implants feature a bone-like structure and cell-friendly surfaces.
“The market is truly stuck debating the differences between two flawed solutions,” said HAPPE Spine Interim CEO Dr. Ryan K. Roeder. “If you value imaging, if you value load sharing, you prefer PEEK. If you value the porosity for bone ingrowth and you value the surface, you prefer titanium. But you couldn’t have it all until, we believe, our product.”
The company is already well-positioned with 11 issued patents covering the material, the manufacturing process, and the implant designs. It has cleared through a 510(k) pathway and established that pathway for future follow-on products.
The technology has been validated in three clinical studies, with more than 2,000 implants put in more than 1,000 patients. HAPPE Spine also has meaningful commercial traction, with more than $2 million in sales in 2025.
Like most of the companies pitching at MNVC, HAPPE Spine has aspirations to be a platform technology. Dr. Roeder said the company is a biomaterial platform validating its technology in spine, but potentially has clinical applications in sports medicine, trauma, and foot and ankle.
We’re proud to be validated by one of the most respected voices in the orthopedic industry. The technology behind HAPPE Spine has been years in the making, and recognition like this reflects the hard work of our team and the surgeons who have trusted us along the way.